Albers Jeffrey W. insider trades
Albers Jeffrey W. has filed 53 Form 4s with the SEC that we hold, for BPMC (Director), Kymera Therapeutics, Inc. (KYMR) (Director), Spyre Therapeutics, Inc. (SYRE) (Director) and Dianthus Therapeutics, Inc. /DE/ (MGTA) (Director). Across all of them we count 0 purchases worth $0 and 80 sales worth $35.9M reported on Form 4. In the last 12 months: 0 purchases ($0) and 6 sales ($3.1M). The largest single trade was a sale of 21,906 shares of BPMC worth $2.5M, dated 2021-11-15. The first filing on our record is dated 2021-08-23 and the latest 2026-08-10.
BPMC
Director · 34 filings · 67 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-08-19 | S, sale reported on Form 4 | 10,185 | $939.2K | 2021-08-23 |
| 2021-08-19 | S, sale reported on Form 4 | 14,815 | $1.4M | 2021-08-23 |
| 2021-11-01 | S, sale reported on Form 4 | 5,000 | $575.8K | 2021-11-03 |
| 2021-11-15 | S, sale reported on Form 4 | 100 | $11.3K | 2021-11-17 |
| 2021-11-15 | S, sale reported on Form 4 | 7,894 | $899.3K | 2021-11-17 |
| 2021-11-15 | S, sale reported on Form 4 | 21,906 | $2.5M | 2021-11-17 |
| 2021-11-15 | S, sale reported on Form 4 | 100 | $11.2K | 2021-11-17 |
| 2022-03-03 | S, sale reported on Form 4 | 7,862 | $473.9K | 2022-03-08 |
| 2022-03-04 | S, sale reported on Form 4 | 1,400 | $83.2K | 2022-03-08 |
| 2022-03-04 | S, sale reported on Form 4 | 10,055 | $569.2K | 2022-03-08 |
| 2022-03-04 | S, sale reported on Form 4 | 4,100 | $238.9K | 2022-03-08 |
| 2022-03-04 | S, sale reported on Form 4 | 4,445 | $256.3K | 2022-03-08 |
| 2022-03-07 | S, sale reported on Form 4 | 4,843 | $272.1K | 2022-03-08 |
| 2022-04-06 | S, sale reported on Form 4 | 5,000 | $350.6K | 2022-04-08 |
| 2022-05-16 | S, sale reported on Form 4 | 1,900 | $103.5K | 2022-05-18 |
| 2022-05-16 | S, sale reported on Form 4 | 5,342 | $297.2K | 2022-05-18 |
| 2022-05-16 | S, sale reported on Form 4 | 12,758 | $717.1K | 2022-05-18 |
| 2022-08-08 | S, sale reported on Form 4 | 10,000 | $700.7K | 2022-08-10 |
| 2022-08-16 | S, sale reported on Form 4 | 7,230 | $491.7K | 2022-08-18 |
| 2022-08-16 | S, sale reported on Form 4 | 12,477 | $856.2K | 2022-08-18 |
| 2022-08-16 | S, sale reported on Form 4 | 293 | $20.4K | 2022-08-18 |
| 2022-08-19 | S, sale reported on Form 4 | 1,590 | $111.3K | 2022-08-23 |
| 2022-08-22 | S, sale reported on Form 4 | 662 | $47.2K | 2022-08-23 |
| 2022-08-22 | S, sale reported on Form 4 | 7,748 | $546.0K | 2022-08-23 |
| 2022-12-05 | S, sale reported on Form 4 | 20,000 | $1.0M | 2022-12-07 |
| 2023-03-06 | S, sale reported on Form 4 | 9,474 | $433.2K | 2023-03-08 |
| 2023-03-06 | S, sale reported on Form 4 | 319 | $14.1K | 2023-03-08 |
| 2023-08-24 | S, sale reported on Form 4 | 15,000 | $743.5K | 2023-08-28 |
| 2023-08-25 | S, sale reported on Form 4 | 10,000 | $501.6K | 2023-08-28 |
| 2023-09-27 | S, sale reported on Form 4 | 400 | $20.2K | 2023-09-29 |
| 2023-09-27 | S, sale reported on Form 4 | 12,102 | $604.3K | 2023-09-29 |
| 2023-09-27 | S, sale reported on Form 4 | 5,600 | $273.5K | 2023-09-29 |
| 2023-09-28 | S, sale reported on Form 4 | 6,898 | $346.1K | 2023-09-29 |
| 2023-11-01 | S, sale reported on Form 4 | 3,881 | $232.9K | 2023-11-03 |
| 2023-11-02 | S, sale reported on Form 4 | 59 | $3.6K | 2023-11-03 |
| 2023-11-02 | S, sale reported on Form 4 | 4,575 | $276.1K | 2023-11-03 |
| 2023-11-03 | S, sale reported on Form 4 | 1,485 | $89.3K | 2023-11-03 |
| 2023-11-24 | S, sale reported on Form 4 | 7,964 | $535.6K | 2023-11-28 |
| 2023-11-24 | S, sale reported on Form 4 | 7,036 | $477.1K | 2023-11-28 |
| 2023-11-30 | S, sale reported on Form 4 | 5,000 | $352.8K | 2023-12-04 |
| 2023-12-11 | S, sale reported on Form 4 | 5,000 | $395.3K | 2023-12-13 |
| 2024-01-25 | S, sale reported on Form 4 | 100 | $8.4K | 2024-01-29 |
| 2024-01-25 | S, sale reported on Form 4 | 7,924 | $655.8K | 2024-01-29 |
| 2024-01-25 | S, sale reported on Form 4 | 10,890 | $889.7K | 2024-01-29 |
| 2024-01-25 | S, sale reported on Form 4 | 6,086 | $493.9K | 2024-01-29 |
| 2024-03-07 | S, sale reported on Form 4 | 11,033 | $1.0M | 2024-03-26 |
| 2024-03-20 | S, sale reported on Form 4 | 2,730 | $232.7K | 2024-03-22 |
| 2024-03-20 | S, sale reported on Form 4 | 6,251 | $540.5K | 2024-03-22 |
| 2024-03-20 | S, sale reported on Form 4 | 8,440 | $736.5K | 2024-03-22 |
| 2024-03-20 | S, sale reported on Form 4 | 6,285 | $556.9K | 2024-03-22 |
| 2024-03-20 | S, sale reported on Form 4 | 1,367 | $121.8K | 2024-03-22 |
| 2024-09-09 | S, sale reported on Form 4 | 7,734 | $658.3K | 2024-09-11 |
| 2024-09-09 | S, sale reported on Form 4 | 11,968 | $1.0M | 2024-09-11 |
| 2024-11-07 | S, sale reported on Form 4 | 5,000 | $510.0K | 2024-11-12 |
| 2024-12-19 | S, sale reported on Form 4 | 2,100 | $193.1K | 2024-12-20 |
| 2024-12-19 | S, sale reported on Form 4 | 3,800 | $346.4K | 2024-12-20 |
| 2024-12-19 | S, sale reported on Form 4 | 5,180 | $461.1K | 2024-12-20 |
| 2024-12-19 | S, sale reported on Form 4 | 3,920 | $346.1K | 2024-12-20 |
| 2025-01-13 | S, sale reported on Form 4 | 5,000 | $511.4K | 2025-01-15 |
| 2025-01-21 | S, sale reported on Form 4 | 7,561 | $825.0K | 2025-01-23 |
| 2025-01-21 | S, sale reported on Form 4 | 7,400 | $813.4K | 2025-01-23 |
| 2025-01-21 | S, sale reported on Form 4 | 200 | $22.1K | 2025-01-23 |
| 2025-03-05 | S, sale reported on Form 4 | 5,766 | $512.0K | 2025-03-17 |
| 2025-03-12 | S, sale reported on Form 4 | 5,700 | $499.4K | 2025-03-14 |
| 2025-03-12 | S, sale reported on Form 4 | 1,800 | $159.1K | 2025-03-14 |
| 2025-05-27 | S, sale reported on Form 4 | 4,350 | $439.4K | 2025-05-29 |
| 2025-05-27 | S, sale reported on Form 4 | 650 | $66.3K | 2025-05-29 |
Kymera Therapeutics, Inc. (KYMR)
Director · 11 filings · 8 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-01-23 | S, sale reported on Form 4 | 10,000 | $300.5K | 2024-01-23 |
| 2024-02-20 | S, sale reported on Form 4 | 615 | $24.0K | 2024-02-21 |
| 2024-02-21 | S, sale reported on Form 4 | 4,385 | $171.2K | 2024-02-21 |
| 2024-08-26 | S, sale reported on Form 4 | 5,000 | $245.5K | 2024-08-26 |
| 2025-06-03 | S, sale reported on Form 4 | 6,349 | $311.1K | 2025-06-03 |
| 2025-10-13 | S, sale reported on Form 4 | 5,000 | $295.9K | 2025-10-14 |
| 2025-12-08 | S, sale reported on Form 4 | 2,252 | $203.4K | 2025-12-08 |
| 2025-12-08 | S, sale reported on Form 4 | 2,748 | $245.5K | 2025-12-08 |
Spyre Therapeutics, Inc. (SYRE)
Director · 7 filings · 5 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-10-25 | S, sale reported on Form 4 | 300 | $10.9K | 2024-10-28 |
| 2024-11-06 | S, sale reported on Form 4 | 6,700 | $246.3K | 2024-11-08 |
| 2026-08-07 | S, sale reported on Form 4 | 5,000 | $522.4K | 2026-08-10 |
| 2026-08-07 | S, sale reported on Form 4 | 8,000 | $835.0K | 2026-08-10 |
| 2026-08-07 | S, sale reported on Form 4 | 10,000 | $1.0M | 2026-08-10 |
Dianthus Therapeutics, Inc. /DE/ (MGTA)
Director · 1 filing · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Source
Counted from the Form 4 filings this reporting owner (SEC CIK 1638474) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms